In this issue of JAMA Pediatrics, Livingston et al1 address the important question of whether a therapy demonstrated to improve the care of adult patients with empyema, the addition of dornase alfa (DNase) to tissue plasminogen activator (tPA) intrapleural therapy, has similar benefits in children. The utility of DNase in adults requiring pleural drainage for empyema has been established in a prior randomized clinical trial by Rahman et al.2 In that study, adult patients who received a combination of intrapleural DNase and tPA had improved pleural effusion size compared with patients receiving DNase alone, tPA alone, and double placebo. Patients receiving the combination treatment also had a 6.7-day reduction in hospital stay (from randomization to discharge) and 77% fewer referrals for thoracic surgery within 3 months compared with patients receiving placebo. In this pediatric study,1 the authors use a pragmatic approach to determine whether the addition of intrapleural DNase to tPA therapy would provide clinically meaningful benefits for otherwise healthy children requiring pleural drainage for empyema when compared with the standard treatment of tPA alone. Chest tube placement with installation of tPA has previously been shown in a randomized clinical trial to be an efficacious primary drainage modality for children with empyema and less costly than primary video-assisted thoracoscopic surgery.3
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Kohler J, Kelly MM. Addition of Dornase to Intrapleural Fibrinolytic Therapy Is Not Superior to Fibrinolytic Therapy Alone for Otherwise Healthy Children Hospitalized With Empyema. JAMA Pediatr. 2020;174(4):323–324. doi:10.1001/jamapediatrics.2019.5910
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: